Achieve Life Sciences Stock Rises on Expedited Review of E-Cig Dependence Treatment
By Katherine Hamilton
Achieve Life Sciences shares jumped after the company said it got a priority voucher for its treatment of nicotine dependence stemming from e-cigarettes and vaping.
The stock was up by about one-third to $4.12. Shares are up about 17% this year.
The U.S. Food and Drug Administration gave the pharmaceutical company a Commissioner's National Priority Voucher, which will expedite review of its treatment cytisinicline, Achieve said Friday. The voucher is designed to shorten the FDA's assessment time to one or two months from the standard 10 to 12 months.
Cytisinicline is a drug intended to help people shake their dependence on vaping and smoking e-cigarettes. It demonstrated clinical efficacy in a phase 2 trial where patients who took the drug were 2.6 times more likely to quit compared to placebo, said the Bothell, Wash.-based company.
The FDA previously granted the drug a breakthrough-therapy designation and approved a phase 3 trial design. It also accepted for review Achieve's new drug application for cytisinicline as a treatment for nicotine dependence for smoking.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 17, 2025 10:31 ET (14:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States